April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Effect of Ozurdex on Macular Edema from Venous Occlusive Disease and Uveitis in a Clinical Practice
Author Affiliations & Notes
  • Shil K. Patel
    Ophthalmology, Associated Retina Consultants, Phoenix, Arizona
  • Mandi Conway, M.D.
    Ophthalmology, Associated Retina Consultants, Phoenix, Arizona
  • Gholam Peyman, M.D.
    Ophthalmology, Associated Retina Consultants, Phoenix, Arizona
  • Shil K. Patel, M.D.
    Ophthalmology, Associated Retina Consultants, Phoenix, Arizona
  • Footnotes
    Commercial Relationships  Shil K. Patel, None; Mandi Conway M.D., None; Gholam Peyman M.D., None; Shil K. Patel M.D., None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4326. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shil K. Patel, Mandi Conway, M.D., Gholam Peyman, M.D., Shil K. Patel, M.D.; Effect of Ozurdex on Macular Edema from Venous Occlusive Disease and Uveitis in a Clinical Practice. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4326. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We evaluated the safety and efficacy of Ozurdex (Allergan Inc., Irvine, CA) intravitreal implants in eyes with macular edema associated with retinal venous occlusive diesease and uveitis in a large retinal practice.

Methods: : Retrospective chart review. Complete eye examinations were performed at each visit and serial Cirrus OCTs were performed at each visit.

Results: : There were 27 eyes (10 males, 14 females) treated with an Ozurdex implant between 11/2009 and 11/2010. Twelve eyes had macular edema associated with BRVO (duration 2 to 69 months), 7 eyes with CRVO (duration 1 to 23 months), and 8 eyes with non- infectious uveitic cystoid macular edema (15 months to 26 years). Mean age was 76 years (58 to 93 years), 74 years (73 to 87 years), and 41 years old (20 to 57 years) for the BRVO, CRVO, and uveitic groups, respectively. In the BRVO group, the mean visual acuity improved by an average of 1.6 Snellen lines from 20/145 to 20/64. In the CRVO group, the mean visual acuity decreased by an average of 0.14 Snellen lines from 20/109 to 20/162. In the uveitic cystoid macular edema group, the mean visual acuity improved by an average of 2 Snellen lines from 20/30 to 20/20. Central foveal thickness, as measured by Cirrus OCT, decreased by an average of 64 microns in the BRVO group, 185.5 microns in the CRVO group, and 182 microns in the uveitic cystoid macular edema groups. No eyes required topical ocular hypotensives for sustained elevated intraocular pressures and there were no serious adverse events. Eleven eyes received 2 intravitreal Ozurdex injections.

Conclusions: : Ozurdex may be more efficacious in improving vision in eyes with macular edema secondary to branch retinal vein occlusions compared to central retinal vein occlusions, although the mean CRT decrease was greater in the central retinal vein occlusion group. Ozurdez may hold promise for the treatment of cystoid macular edema associated with non infectious uveitis and vitritis, although our sample size is small. Ozurdex is a safe implant and we had no serious adverse events related to implantation.

Keywords: edema • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×